High materiality9/10
Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
Why it may matterVerify against the original reporting
Very bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley raises target to $38 vs price $27.1; implied upside ~40%.
- Morgan Stanley target $38 vs price $27.1; ~40% upside.
Key facts
- 01
Target: $38
- 02
Posted price: $27.1
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.